PTO/SB/08a (01-10)
Approved for use through 07/31/2012. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10575977
Filing Date	2007-05-02
First Named Inventor	Haijun Sun
Art Unit	1647
Examiner Name	DEBERRY, Regina M
Attorney Docket Number	X-18530

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] ¡	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1							☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575977
	Filing Date	2007-05-02
	First Named Inventor	Haijun Sun
	Art Unit	1647
	Examiner Name	DEBERRY, Regina M
	Attorney Docket Number	X-18530

	1	ABATH and SIMPSON, Peptide Research, 3(4):167-168 (1990)	☐
	2	AUSUBEL et al., Current Protocols in Molecular Biology, 1:2.20.3, Green Publishing Associates, Inc., and John Wiley & Sons, Inc, New York (1989)	☐
	3	BAYES et al., "Gateways To Clinical Trials." Methods and Findings in Experimental and Clinical Pharmacology, 25(6):483-506 at 491, Prous, Barcelona, Spain (July 2003)	☐
	4	BLANCKAERT et al., "Partial characterization of endothelial FGF receptor functional domain by monoclonal antibody VBS-1. "Hybridoma and Hybridomics, 21(3): 153-159 (June 2002)	☐
	5	BOERNER et al., J. Immunol, 147(1):86-95 (1991)	☐
	6	DIECKMANN and TZAGOLOFF, J. Biol. Chem., 260:1513-1520 (1985)	☐
	7	FISHWILD et al., Nature Biotechnology, 14:845-51 (1996)	☐
	8	SMITH, et al., Gene, 67:31-40 (1988)	☐
	9	HOOGENBOOM and WINTER, J. Mol Biol., 227:381 (1991)	☐
	10	JOHNSON et al., "The human fibroblast growth factor receptor genes: a common structural arrangement underlies the mechanisms for generating receptor forms that differ in their third immunoglobulin domain." Molecular and Cellular Biology, 11(9):4627-4634 (September 1991)	☐
	11	KAUFMANN and SHARP, "Amplification and Expression of Sequences Cotransfected with A Modular Dihydorfolate Reductase Complementary DNA Gene." J. Mol. Biol., 159:601-621 (1982)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575977
	Filing Date	2007-05-02
	First Named Inventor	Haijun Sun
	Art Unit	1647
	Examiner Name	DEBERRY, Regina M
	Attorney Docket Number	X-18530

	12	KOSTRZEWA et al., "Genomic structure and complete sequence of the human FGFR4 gene." Mammalian Genome: Official Journal of the International Mammalian Genome Society, 9(2):131-135 (February 1998)	☐
	13	LONBERG and HUSZAR, Intern Rev. Immunol, 13:65-93 (1995)	☐
	14	LONBERG et al., Nature, 368:856-859 (1994)	☐
	15	MARKS et al., J. Mol. Biol., 222:581 (1991)	☐
	16	MORRISON, Nature, 368:812-813 (1994)	☐
	17	NEUBERGER, Nature Biotechnology, 14:826 (1996)	☐
	18	PARTRIDGE et al., "Overexpression of a secretory form of FGF-1 promotes MMP-1-mediated endothelial cell migration." Journal of Cellular Biochemistry, 78(3):487-499 (June 6, 2000)	☐
	19	POWERS et al., "Fibroblast growth factors, their receptors and signaling." Endocrine Related Cancer, 7:165-197 at 165-197 (2000)	☐
	20	SKAPER et al., "The FGFR1 inhibitor PD 173074 selectively and potently antagonizes FGF-2 neurotrophic and neurotropic effects." Journal of Neurochemistry, 75(4):1520-1527 (October 2000)	☐
	21	SOUTHERN and BERG, J. Mol. Appl. Genet., 1:327-341 (1982)	☐
	22	STEGER et al., "Localization of fibroblast growth factor 2 (FGF-2) protein and the receptors FGFR 1-4 in normal human seminiferous epithelium." Histochemistry and Cell Biology, 110(1):57-62, Germany (1998)	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575977
	Filing Date	2007-05-02
	First Named Inventor	Haijun Sun
	Art Unit	1647
	Examiner Name	DEBERRY, Regina M
	Attorney Docket Number	X-18530

	23	SUN et al., "Monoclonal antibody antagonists of hypothalamic FGFR1 cause potent but reversible hypophagia and weight loss in rodents and monkeys." American Journal of Physiology, Endocrinology and Metabolism, 292(3):E964-E976 (March 2007)	☐
	24		☐
	25		☐
	26		☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.